FSRH statement: MHRA changes its regulatory position on sodium valproate


Published on: 24 April 2018

File size: 98kb PDF

File type: FSRH Response

On 24 April the Medicines and Healthcare Products Regulatory Agency (MHRA) changed its regulatory position on medicines containing sodium valproate. MHRA advises that if a woman of childbearing age is to be prescribed sodium valproate, she must be enrolled in a pregnancy prevention programme (PPP). This FSRH statement outlines the implications for daily practice.

Your download should start automatically. If not download directly.